Literature DB >> 31640966

[Correlation between serum 25(OH) vitamin D and liver fat content in nonalcoholic fatty liver disease].

Likun Fu1, Hongmei Cui1, Kunling Lu1, Chunyan Zou1, Guixian Ji1, Li Li1, Jinglong Li1, Lina Sheng1, Changshun Xie1.   

Abstract

OBJECTIVE: To investigate the relationship between serum 25(OH) vitamin D and liver fat content in nonalcoholic fatty liver disease (NAFLD).
METHODS: A total of 120 patients with NAFLD admitted in our hospital between June and August, 2017 were enrolled and divided into 4 groups with different serum 25 (OH) vitamin D levels: >75 nmol/L (group A, n=25), 50-75 nmol/L (group B, n=35), 25-50 nmol/L (group C, n=32), and < 25 nmol/L (group D, n=28). For all the patients, serum 25 (OH) vitamin D level was measured by ELISA, and liver fat content was determined using in-phase opposed-phase T1WI sequences. The measurement data were compared among the 4 groups to assess the association between serum 25(OH) vitamin D level and liver fat content.
RESULTS: The liver fat content appeared to be higher in group B (28.66±6.45%) and group C (38.74±11.47%) than in group A (22.79 ± 6.10%), but the difference was not statistically significant (P>0.05); the liver fat content in group D (54.79 ± 5.28%) was significantly higher than that in the other 3 groups (P>0.05). Liver fat content increased significantly as serum 25(OH) vitamin D level decreased, showing an inverse correlation between them in these patients (P < 0.05, r=-0.125).
CONCLUSIONS: In patients with NAFLD, a decreased serum 25(OH) vitamin D level is associated with an increased liver fat content, suggesting the value of serum 25(OH) vitamin D as a predictor of NAFLD.

Entities:  

Keywords:  liver fat content; nonalcoholic fatty liver disease; serum 25 (OH) vitamin D

Mesh:

Substances:

Year:  2019        PMID: 31640966      PMCID: PMC6881731          DOI: 10.12122/j.issn.1673-4254.2019.09.19

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  13 in total

1.  Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis.

Authors:  Xiang Wang; Weiping Li; Ying Zhang; Yang Yang; Guijun Qin
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Response kinetics and factors predicting survival in core-binding factor leukemia.

Authors:  Prajwal Boddu; Christopher Gurguis; David Sanford; Jorge Cortes; Mary Akosile; Farhad Ravandi; Guillermo Garcia-Manero; Keyur P Patel; Tapan Kadia; Mark Brandt; Rita Maduike; Hagop Kantarjian; Gautam Borthakur
Journal:  Leukemia       Date:  2018-06-08       Impact factor: 11.528

3.  [Clinical Importance of Non-alcoholic Fatty Liver Diseases. Topics: V. Extrahepatic manifestations: cerebral and cardiovascular diseases, chronic kidney disease].

Authors:  Kento Imajo; Masato Yoneda; Atsushi Nakajima
Journal:  Nihon Naika Gakkai Zasshi       Date:  2016-01-10

4.  Low circulating 25-hydroxyvitamin D concentrations are associated with defects in insulin action and insulin secretion in persons with prediabetes.

Authors:  Fahim Abbasi; Christine Blasey; David Feldman; Michael P Caulfield; Feras M Hantash; Gerald M Reaven
Journal:  J Nutr       Date:  2015-03-04       Impact factor: 4.798

5.  Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies.

Authors:  ZhanZhan Li; Jing Xue; Peng Chen; LiZhang Chen; ShiPeng Yan; LiYa Liu
Journal:  J Gastroenterol Hepatol       Date:  2014-01       Impact factor: 4.029

6.  Prevalence of vitamin D deficiency in chronic liver disease.

Authors:  J Arteh; S Narra; S Nair
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

7.  Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods.

Authors:  Gaspard d'Assignies; Martin Ruel; Abdesslem Khiat; Luigi Lepanto; Miguel Chagnon; Claude Kauffmann; An Tang; Louis Gaboury; Yvan Boulanger
Journal:  Eur Radiol       Date:  2009-03-11       Impact factor: 5.315

8.  Vitamin D Signaling through Induction of Paneth Cell Defensins Maintains Gut Microbiota and Improves Metabolic Disorders and Hepatic Steatosis in Animal Models.

Authors:  Danmei Su; Yuanyang Nie; Airu Zhu; Zishuo Chen; Pengfei Wu; Li Zhang; Mei Luo; Qun Sun; Linbi Cai; Yuchen Lai; Zhixiong Xiao; Zhongping Duan; Sujun Zheng; Guihui Wu; Richard Hu; Hidekazu Tsukamoto; Aurelia Lugea; Zhenqui Liu; Stephen J Pandol; Yuan-Ping Han
Journal:  Front Physiol       Date:  2016-11-15       Impact factor: 4.566

Review 9.  Non-alcoholic fatty liver disease: an update on diagnosis.

Authors:  Dan L Dumitrascu; Manuela G Neuman
Journal:  Clujul Med       Date:  2018-04-25

10.  Quality of medication services for morbidities in a rural health center in Puducherry, India.

Authors:  Sivakumar Dharmasivam; Ramya Selvaraj; Subitha Lakshminarayanan; Sitanshu Sekhar Kar; S Ganesh Kumar
Journal:  J Family Med Prim Care       Date:  2017 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.